Clinical trials: Stage II Skin Cancer
Metastatic Breast Cancer
A Phase II Combination of Trastuzumab and Ixabepilone Versus Trastuzumab and Docetaxel in Patients With Advanced and/or Metastatic Breast Cancer
The purpose of this randomized, Phase 2 open-label study was to assess the response rate of participants with Human Epidermal Growth Factor Receptor 2 (Her2+) locally advanced and/or metastatic breast cancer (not previously…
- Trial name
- NCT00490646
- Testing
- ixabepilone, docetaxel, trastuzumab
- Where
- 19 sites in France, Greece and 3 more
- Volunteers
- 50 people
- Sponsor
- R-Pharm
Breast Cancer
A Study of Subcutaneously Administered Herceptin (Trastuzumab) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer
This open-label, randomized crossover study evaluated the quality of life, efficacy, and safety of subcutaneous Herceptin (trastuzumab) injected either into the thigh or the upper arm of participants with early HER2-positive…
- Trial name
- LISAH (NCT01928615)
- Testing
- Trastuzumab - intravenous solution, Trastuzumab - subcutaneous solution, Chemotherapy
- Where
- 2 sites in Austria
- Volunteers
- 2 people
- Sponsor
- Hoffmann-La Roche
Colorectal Cancer, Colon Cancer
Safety Study of hMN14 to Treat Either Colorectal or Breast Cancer
The purpose of this trial is to determine the safety of hMN14 at different dose levels in the treatment of either colorectal or breast cancer.
- Conditions
- Colorectal Cancer, Colon Cancer, Rectal Cancer, Colorectal Neoplasms
- Trial name
- NCT00041652
- Testing
- hMN14 (labetuzumab)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Gilead Sciences
Advanced Breast Cancer
A Study of Everolimus Plus Exemestane in Chinese Postmenopausal Women With Estrogen Receptor Positive, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Non-steroidal Aromatase Inhibitor
This study aimed at evaluating the safety and efficacy of everolimus plus exemestane in Chinese postmenopausal women with ER+ HER2- locally advanced, recurrent, or metastatic breast cancer after recurrence or progression on…
- Trial name
- BOLERO-5 (NCT03312738)
- Testing
- Everolimus, Exemestane
- Where
- 15 sites in China
- Volunteers
- 159 people
- Sponsor
- Novartis Pharmaceuticals
Locally Advanced Breast Cancer, Triple Negative Breast Cancer
Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy
This study is a Phase II, multi-site, randomized, open-label clinical study to evaluate the safety, efficacy, and pharmacokinetics (PK) of BNT327 at two dose levels in combination with chemotherapeutic agents in the first- and…
- Conditions
- Locally Advanced Breast Cancer, Triple Negative Breast Cancer, Metastatic Triple Negative Breast Cancers
- Trial name
- NCT06449222
- Testing
- BNT327 Dose Level 1 (DL1), BNT327 Dose Level 1 (DL2), Nab-placlitaxel
- Where
- 31 sites in United States, Australia and 2 more
- Volunteers
- 83 people
- Sponsor
- BioNTech SE
Metastatic Breast Cancer
Gemcitabine Plus Cisplatin Single Dose Versus Split Dose in the Treatment of Patients With Locally Advanced or Metastatic Breast Cancer After Failure of Anthracyclines and/or Taxanes
This is an open label, two arms, randomized, unblinded phase 2 study in patients with locally advanced or metastatic breast cancer who have been previously treated with anthracycline with/without taxane based regimen in the…
- Trial name
- NCT00192101
- Testing
- gemcitabine, cisplatin
- Where
- Saudi Arabia
- Volunteers
- 100 people
- Sponsor
- Eli Lilly and Company
Breast Cancer
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)
This randomized phase 3 trial is studying the effect of denosumab to see if it can prevent disease recurrence in the bone or in any other part of the body, when it is given as adjuvant therapy for women with early-stage breast…
- Trial name
- NCT01077154
- Testing
- Denosumab
- Where
- 459 sites in United States, Argentina and 37 more
- Volunteers
- 4,509 people
- Sponsor
- Amgen
Sarcoma, Kaposi, HIV Infections
The Safety and Effectiveness of Ritonavir in the Treatment of HIV-Related Kaposi's Sarcoma
To evaluate the safety and anti-Kaposi's sarcoma activity of ritonavir.
- Trial name
- NCT00002366
- Testing
- Ritonavir
- Where
- 2 sites in Australia
- Sponsor
- Abbott
Condyloma
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Twice Daily Topical Applications of AP611074 5% Gel for up to 16 Weeks in Condyloma Patients
This is a double-blind placebo controlled, randomized, phase 2 study to assess the safety, tolerability, pharmacokinetics and efficacy of twice daily topical applications of AP611074 5% Gel for up to 16 weeks in condyloma patients
- Trial name
- NCT02724254
- Testing
- AP611074 5% gel
- Where
- 12 sites in Argentina, Chile and 2 more
- Volunteers
- 218 people
- Sponsor
- Vaxart
Breast Carcinoma
Phase II Study of AS1402 Combined With Letrozole to Treat Breast Cancer
The aim of this study is to compare the overall tumour response rate per RECIST in postmenopausal women with metastatic or locally advanced breast cancer receiving AS1402 in combination with letrozole compared to letrozole alone
- Trial name
- NCT00770354
- Testing
- AS1402, Letrozole
- Where
- 2 sites in Russia
- Volunteers
- 110 people
- Sponsor
- Antisoma Research
Triple-negative Breast Cancer
Establishing the Recommended Biological Dose for AE37 Peptide Vaccine in Combination With Pembrolizumab That Will Enhance the Tumor-specific Immune Response and Demonstrate Efficacy in Patients With Advanced Triple-negative Breast Cancer
This study will look to establish the recommended biologic dose of AE37 in combination with pembrolizumab that will enhance the tumor-specific immune response and demonstrate efficacy in patients with advanced triple-negative…
- Trial name
- NSABP FB-14 (NCT04024800)
- Testing
- AE37 Peptide vaccine, Pembrolizumab
- Where
- 6 sites in United States
- Volunteers
- 29 people
- Sponsor
- NuGenerex Immuno-Oncology
Melanoma
A-dmDT390-bisFv(UCHT1) Fusion Protein in Combination With Ionizing Radiation for Treatment of Stage IV Melanoma
The purpose of this trial is to study A-dmDT390-bisFv(UCHT1) in combination with ionizing irradiation for the treatment of stage IV melanoma, a disease that is essentially incurable with median overall survival periods that range…
- Trial name
- NCT01888081
- Testing
- A-dmDT390-bisFv(UCHT1) (Resimmune®), Ionizing Radiation
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Virogen Biotechnology Inc.
Carcinoma, Basal Cell, Carcinoma, Cutaneous Squamous Cell
Intratumoral Administration of Daromun in Non-melanoma Skin Cancer Patients
This clinical phase II study is designed to investigate the efficacy of intratumorally administered L19IL2/L19TNF in patients with injectable lesions of BCC or cSCC.
- Trial name
- DUNCAN (NCT04362722)
- Testing
- L19IL2 +L19TNF
- Where
- 11 sites in Germany, Poland and 1 more
- Volunteers
- 40 people
- Sponsor
- Philogen S.p.A.
Melanoma
A Study for the Treatment of Unresectable Stage III or Metastatic Stage IV Melanoma
A study with YM155 for the treatment of unresectable stage III or metastatic stage IV melanoma.
- Trial name
- NCT00281541
- Testing
- YM155
- Where
- 9 sites in United States
- Volunteers
- 29 people
- Sponsor
- Astellas Pharma Inc
Metastatic Breast Cancer
Lipo-dox and Cyclophosphamide /5-Fluorouracil in Patients With Metastatic Breast Cancer
To determine the overall objective response rate of pegylated liposomal doxorubicin （Lipo-Dox）combined with cyclophosphamide/5-FU as second-line treatment in patients with metastatic breast cancer.
- Trial name
- NCT01451580
- Testing
- Lipo-Dox
- Where
- Taiwan
- Volunteers
- 47 people
- Sponsor
- TTY Biopharm
Breast Neoplasms, Neoplasm Metastasis
Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases
The aim of this study is to investigate the efficacy and safety of afatinib alone or in combination with vinorelbine, as treatment in patients with HER2-overexpressing metastatic breast cancer, who have progressive brain lesions…
- Trial name
- NCT01441596
- Testing
- Vinorelbine, Investigator's choice of treatment, afatinib
- Where
- 40 sites in United States, Canada and 6 more
- Volunteers
- 121 people
- Sponsor
- Boehringer Ingelheim
Breast Neoplasms, Neoplasm Metastasis
Study in Women With Metastatic Breast Cancer Whose Cancer Has Gotten Worse After Anthracycline and Taxane Therapy
This international study will study how metastatic breast cancer responds to the investigational drug treatment, what are the side effects of the investigational drug when given to women with metastatic breast cancer and how…
- Trial name
- NCT00067314
- Testing
- Edotecarin
- Where
- 19 sites in United States, Australia and 2 more
- Volunteers
- 65 people
- Sponsor
- Pfizer
Breast Neoplasms
Efficacy And Safety Of Sunitinib In Women With Advanced Breast Cancer
Patients with advanced breast cancer to receive sunitinib (Sutent) once daily until disease progression.
- Trial name
- NCT00471276
- Testing
- sunitinib
- Where
- 31 sites in United States
- Volunteers
- 83 people
- Sponsor
- Pfizer
SCC - Squamous Cell Carcinoma of Skin
Non-comparative Study of IFX-1 Alone or IFX-1+Pembrolizumab in Patients With Locally Advanced or Metastatic cSCC.
This is an open-label, "non comparative", non-randomized, Phase II study. Patients will be enrolled in 2 treatment arms
- Trial name
- NCT04812535
- Testing
- Vilobelimab, Vilobelimab + pembrolizumab combination therapy
- Where
- 25 sites in United States, Belgium and 3 more
- Volunteers
- 30 people
- Sponsor
- InflaRx GmbH
Breast Cancer
Study Evaluating the Safety and Efficacy of Onartuzumab And/or Bevacizumab in Combination With Paclitaxel in Participants With Metastatic, Triple Negative Breast Cancer
This is a randomized, Phase II, double-blind, multicenter, placebo-controlled trial designed to preliminarily estimate the efficacy and evaluate the safety and tolerability of onartuzumab (MetMAb) + bevacizumab + paclitaxel and…
- Trial name
- NCT01186991
- Testing
- Onartuzumab, Bevacizumab, Paclitaxel
- Where
- 53 sites in United States, Belgium and 4 more
- Volunteers
- 185 people
- Sponsor
- Genentech, Inc.